NRD
ENTA icon

Nebula Research & Development’s Enanta Pharmaceuticals ENTA Stock Holding History

Nebula Research & Development’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-15,745
Closed -$275K – 860
2024
Q1 		$275K Sell
15,745
-2,723
-15% -$36K 0.06% 562
2023
Q4 		$174K Buy
+18,468
New +$172K 0.05% 565

Other funds holding ENTA

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Nebula Research & Development's ENTA Position: Q2 2024 in Review

Nebula Research & Development sold out of Enanta Pharmaceuticals (ENTA) in Q2 2024, closing a stake of 15,745 shares — an estimated $275K sold.

Nebula Research & Development first reported a position in ENTA in Q4 2023 and held it in 2 quarters. The position peaked at $275K in Q1 2024. 100 funds tracked by Wall St. Rank hold ENTA as of Q2 2024.

  • Nebula Research & Development reported no remaining Enanta Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Nebula Research & Development sold 15,745 Enanta Pharmaceuticals shares in Q2 2024, an estimated $275K.
  • Nebula Research & Development first reported a position in Enanta Pharmaceuticals in Q4 2023 and held it in 2 quarters.
  • Nebula Research & Development's Enanta Pharmaceuticals position peaked at $275K in Q1 2024.
  • 100 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q2 2024.

Based on Nebula Research & Development's 13F filing for Q2 2024, filed 14 Aug 2024.